On May 11, 2020 Senti Biosciences, Inc., the gene circuit company focused on outsmarting complex diseases with intelligent medicines, reported upcoming oral and poster presentations at the 23rd Annual Meeting of the American Society for Gene and Cell Therapies (ASGCT) (Free ASGCT Whitepaper), being held May 12-15, 2020 in a virtual format (Press release, Senti Biosciences, MAY 11, 2020, View Source [SID1234557527]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited about this opportunity to further showcase the potential of our gene circuit platform in oncology," said Tim Lu, M.D., Ph.D., CEO and cofounder of Senti Biosciences. "At ASGCT (Free ASGCT Whitepaper), we are presenting data on in vivo gene therapies, which are equipped with computer-like logic to target tumors in a highly specific manner. Additionally, we will highlight new preclinical data on SENTI-101, an allogeneic cell therapy genetically modified to express a potent combination of cytokines, which give us confidence in its therapeutic potential as we progress towards IND submission."
Details of the presentations are listed below:
ASGCT Annual Meeting, May 12-15, 2020
Title: Tumor-Selective Gene Circuits Enable Highly Specific Localized Cancer Immunotherapy
Abstract Number: 17
Oral Presentation Session: Cancer — Targeted Gene and Cell Therapy
Presentation Date and Time: May 12, 10:45 a.m. – 11:00 a.m. EDT
Presenter: Russell Gordley, Ph.D.
Title: Phenotypic and Functional Characterization of Gene Circuit Modified Allogeneic Mesenchymal Stromal Cells (MSCs) for Solid Tumor Immunotherapy
Abstract Number: 783
Poster Session: Cancer — Targeted Gene and Cell Therapy
Presentation Date and Time: May 13, 5:30 p.m. – 6:30 p.m. EDT
Presenter: Dharini Iyer, Ph.D.
Title: SENTI-101, an Allogeneic Cell Product Expressing a Combination of Cytokines, Promotes Anti-Tumor Immunity in a Syngeneic Orthotopic Model of Pancreatic Ductal Adenocarcinoma
Abstract Number: 1180
Poster Session: Cancer — Targeted Gene and Cell Therapy
Presentation Date and Time: May 14, 5:30 p.m. – 6:30 p.m. EDT
Presenter: Ori Maller, Ph.D.